Kendal A P, Bozeman F M, Ennis F A
Infect Immun. 1980 Sep;29(3):966-71. doi: 10.1128/iai.29.3.966-971.1980.
Purified concentrates of influenza A/USSR/90/77(H1N1)-like, A/Texas/1/77 (H3N2)-like, and B/Hong Kong/5/72-like viruses used for preparation of investigational and licensed vaccines in 1978 to 1979 were tested for their content of neuraminidase enzyme activity. Concentrates of H1N1 virus used to prepare vaccines for clinical investigations performed in the spring of 1978 had neuraminidase activity at that time which decreased during storage to almost undetectable levels (three lots) or by 50% (one lot) by the winter of 1978. Several other lots of concentrates prepared with H1N1 virus and used for vaccine formulation had no detectable neuraminidase enzyme activity when tested in the winter of 1978, at a time when they would be administered in vaccines. The range of specific activity for different lots of concentrates was about 40-fold for A/Texas/1/77, B/Hong Kong/5/72, and A/USSR/90/77 neuraminidases. Immunogenicity of investigational vaccines prepared with tested concentrates and administered between April and July 1978 was measured in volunteers aged 13 to >50 years. Frequency of neuraminidase antibody rises to two doses of H1N1-containing vaccine was 10% in unprimed subjects aged <26 years and about 18 to 36% in older persons. The frequency of neuraminidase antibody rises to one dose of H3N2-containing vaccine varied from 0 to 32% in different groups (mean, 18%). The frequencies of neuraminidase antibody responses were always much lower than the frequencies of hemagglutinin antibody responses. These observations confirm the existence of practical difficulties in achieving uniformity of the neuraminidase content in influenza vaccines and of ensuring good immunogenicity of vaccine neuraminidase even in primed populations.
对1978年至1979年用于制备研究性疫苗和已获许可疫苗的甲型/苏联/90/77(H1N1)类似株、甲型/得克萨斯/1/77(H3N2)类似株和乙型/香港/5/72类似株流感病毒的纯化浓缩物进行了神经氨酸酶酶活性含量检测。1978年春季用于制备临床研究疫苗的H1N1病毒浓缩物当时具有神经氨酸酶活性,在储存过程中,到1978年冬季,其中三批降至几乎检测不到的水平,一批下降了50%。1978年冬季检测时,其他几批用H1N1病毒制备并用于疫苗配方的浓缩物在用于疫苗接种时未检测到神经氨酸酶酶活性。不同批次浓缩物中,甲型/得克萨斯/1/77、乙型/香港/5/72和甲型/苏联/90/77神经氨酸酶的比活性范围约为40倍。1978年4月至7月间,用检测过的浓缩物制备并接种给13岁至50岁以上志愿者的研究性疫苗的免疫原性进行了测定。未接种过疫苗的26岁以下受试者中,接种两剂含H1N1疫苗后神经氨酸酶抗体升高的频率为10%,年龄较大者中约为18%至36%。接种一剂含H3N2疫苗后神经氨酸酶抗体升高的频率在不同组中从0%至32%不等(平均为18%)。神经氨酸酶抗体反应的频率总是远低于血凝素抗体反应的频率。这些观察结果证实了在实现流感疫苗中神经氨酸酶含量的一致性以及确保疫苗神经氨酸酶即使在已接种人群中也具有良好免疫原性方面存在实际困难。